What is REGN727/SAR236553 and what condition does it aim to treat?

REGN727/SAR236553 is an investigational monoclonal antibody being developed by Regeneron. The data presented concerns its use in treating hypercholesterolemia, specifically heterozygous familial and non-familial forms, by inhibiting PCSK9 to lower LDL-C levels.

What were the key findings of the Phase 1b study?

The Phase 1b study demonstrated that REGN727/SAR236553 effectively reduced LDL-C levels in patients with hypercholesterolemia. Importantly, it showed efficacy when used either alone (monotherapy) or in combination with other cholesterol-lowering treatments (add-on therapy).

Where can investors find more detailed information about these study results?

Investors can find the detailed presentation slides by referring to Exhibit 99.1, titled 'Inhibition of PCSK9 with Monoclonal Antibody REGN727/SAR236553 Effectively Reduces LDL-C as Mono or Add-on Therapy in Heterozygous Familial and Non-Familial Hypercholesterolemia,' which is furnished with this Form 8-K filing.

Is this drug already approved for use?

No, the filing indicates that REGN727/SAR236553 is an investigational drug. The data presented is from a Phase 1b study, which is an early stage of clinical development. Further trials would be required for potential regulatory approval.

REGN 8-K: Regulation FD

Summary

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on November 14, 2011, to disclose the presentation of data from a Phase 1b study of its investigational drug REGN727/SAR236553. This study focused on patients with hypercholesterolemia, specifically those with heterozygous familial and non-familial forms of the condition. The data, presented at the American Heart Association Scientific Session 2011, demonstrated REGN727/SAR236553's ability to effectively reduce LDL-C (low-density lipoprotein cholesterol) when used as either a standalone therapy or as an add-on to existing treatments.

Key Highlights

1Presentation of Phase 1b study data for REGN727/SAR236553 at the American Heart Association Scientific Session 2011.
2REGN727/SAR236553 is an investigational monoclonal antibody targeting PCSK9.
3Study evaluated REGN727/SAR236553 in patients with heterozygous familial and non-familial hypercholesterolemia.
4Data showed effective reduction of LDL-C as both monotherapy and add-on therapy.
5The presentation slides are furnished as an exhibit (Exhibit 99.1) to the 8-K filing.
6This data is significant for investors as it pertains to a potential new treatment for high cholesterol, a widespread health concern.

REGENERON PHARMACEUTICALS, INC. 8-K Report, Regulation FD Disclosure (Nov 14, 2011)

Summary

Key Highlights

Frequently Asked Questions